Clinical Misrepresentation

From 2008-2018, a third of clinical trials that produced new cancer drugs failed to report the race of participants.

A new study also found that even among trials that did, participation numbers were not representative of the general cancer patient population: just 6% Hispanic and 3% black. 

NIH-funded studies require representation proportionate to the general population but most drug approval trials are funded by drug companies, which do not.

“Clinical trials that establish FDA approval or standard of care [for a new drug] should definitely be representative of the population it’s used to treat,” says study author Kanwal Raghav. “If it’s not, why?”


Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top